Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
15.03. | TScan Therapeutics' (TCRX) "Overweight" Rating Reiterated at Morgan Stanley | 4 | MarketBeat | ||
06.03. | Needham & Company LLC Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $9.00 | 2 | MarketBeat | ||
06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
05.03. | TScan Therapeutics files for $300M mixed securities shelf | 1 | Seeking Alpha | ||
05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
26.12.24 | Why Is TScan Therapeutics Stock Gaining Today? | 3 | Benzinga.com | ||
26.12.24 | TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium | - | RTTNews | ||
26.12.24 | TScan Therapeutics announces ~$30M direct offering | 1 | Seeking Alpha | ||
26.12.24 | TScan sichert sich 30 Millionen US-Dollar durch Optionsscheinverkauf an Lynx1 | 4 | Investing.com Deutsch | ||
26.12.24 | TScan secures $30 million through warrant sale to Lynx1 | 1 | Investing.com | ||
26.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium | 2 | GlobeNewswire (USA) | ||
23.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank | 1 | GlobeNewswire (USA) | ||
23.12.24 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
11.12.24 | The Analyst Landscape: 5 Takes On TScan Therapeutics | 1 | Benzinga.com | ||
10.12.24 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | TScan Therapeutics, Inc.: TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 86,90 | -1,36 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
MEDIGENE | 0,750 | -6,25 % | PTA-Adhoc: Medigene AG: Verlustanzeige nach § 92 AktG und Anpassung der der Liquiditätsreichweite | DJ PTA-Adhoc: Medigene AG: Verlustanzeige nach § 92 AktG und Anpassung der der Liquiditätsreichweite
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Medigene AG: Verlustanzeige... ► Artikel lesen | |
AMGEN | 283,45 | +0,50 % | Which Dow Jones Stock Is Cheaper, Amgen or Merck? | ||
BIOFRONTERA | 2,500 | -2,72 % | Top-Zock 2025: Formycon, Biofrontera oder BB Biotech? | Auf der Suche nach unserem Top-Zock 2025 haben wir unzählige Small- und Nano-Cap-Titel analysiert. Ein Wert sticht dabei mit einem überragenden Chance-Risiko-Profil über die nächsten Monate heraus.... ► Artikel lesen | |
BIOGEN | 127,55 | -0,08 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 592,00 | +0,68 % | Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low - What's Next? | ||
EDITAS MEDICINE | 1,158 | -0,13 % | Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition | Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.... ► Artikel lesen | |
AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
GALAPAGOS NV | 23,660 | +0,34 % | Galapagos NV: Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting | Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders'... ► Artikel lesen | |
IMMATICS | 4,242 | -0,70 % | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
AUTOLUS THERAPEUTICS | 1,520 | -3,80 % | Autolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Recommendation of "Buy" by Brokerages | ||
IGM BIOSCIENCES | 1,120 | -2,61 % | IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs | - Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December... ► Artikel lesen | |
ONCOPEPTIDES | 0,132 | -2,94 % | Oncopeptides AB: Oncopeptides publishes year-end report 2024 | Stockholm - February 27, 2025 - Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024.
"Pepaxti sales increased about 35 percent... ► Artikel lesen | |
AVACTA | 0,394 | -1,00 % | AVACTA GROUP PLC: Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting |